Eiger BioPharmaceuticals

About

Eiger is a biopharmaceutical company that develops new antiviral agents against novel targets in the treatment of hepatitis.

San Carlos,California,United States
1 - 10
http://www.eigerbio.com

Highlights

Details

Last Funding Type: Post-IPO Debt
Last Funding Money Raised: $75M
Industries: Biotechnology,Health Care,Medical
Founded date: Jan 1, 2008
Number Of Employee: 1 - 10
Operating Status: Active
Stock Symbol: nasdaq:EIGR
Legal Name: Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals is a privately held biotechnology company that develops a novel antiviral therapy for Hepatitis Delta, a life-threatening, Orphan Disease with high unmet medical need and no approved therapy.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Its strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

11

$156.26M

Eiger BioPharmaceuticals has raised a total of $156.26M in funding over 2 rounds. Their latest funding was raised on Jun 7, 2022 from a Post-IPO Debt round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Jun 7, 2022	Post-IPO Debt	$75M	1	Innovatus Capital Partners	—	Detail
Jun 7, 2022	Post-IPO Equity	$5M	1	Innovatus Capital Partners	—	Detail
Oct 26, 2017	Post-IPO Equity	$19.50M	—	—	—	Detail
Jan 4, 2017	Post-IPO Debt	$25M	1	Oxford Finance LLC	—	Detail
Apr 29, 2016	Post-IPO Equity	$2.99M	—	—	—	Detail

Investors

Number of Lead Investors

Number of Investors

5

Eiger BioPharmaceuticals is funded by 5 investors. Innovatus Capital Partners and Oxford Finance LLC are the most recent investors.

Investor Name	Lead Investor	Funding Round
Innovatus Capital Partners	Yes	Post-IPO Debt
Oxford Finance LLC	Yes	Post-IPO Debt
InterWest Partners	—	Debt Financing
Vivo Capital	—	Series A
RA Capital Management	—	Seed